Avalo Therapeutics, Inc. (AVTX)
Key Executives
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Dr. Garry A. Neil M.D. | Chairman of the Board, President & CEO | 475k | -- | 1954 |
Mr. Christopher Ryan Sullivan | CFO & Head of Investor relations | 350k | -- | 1984 |
Dr. Solomon H. Snyder M.D. | Founder and Chairman of Scientific Advisory Board | -- | -- | 1939 |
Dr. Barbara S. Slusher Ph.D. | Founder and Member of Scientific Advisory Board | -- | -- | 1965 |
Dr. Lisa Hegg Ph.D. | Senior Vice President of Program Management, Corporate Infrastructure & Clinical Operations | -- | -- | -- |
Ms. Colleen Matkowski | Senior Vice President of Global Regulatory Affairs & Quality Assurance | -- | -- | -- |
Dr. Dino C. Miano Ph.D. | Senior Vice President of CMC & Technical Operations | -- | -- | -- |
Avalo Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 19
Description
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
Corporate Governance
Upcoming Events
August 1, 2024 at 12:30 PM UTC - August 5, 2024 at 12:30 PM UTC
Avalo Therapeutics, Inc. Earnings Date
Recent Events
March 28, 2024 at 12:30 PM UTC
Acquires Anti-IL-1ß mAb and Announces up to $185M Private Placement Conference Call